The peptide exercise writes

Search for MOTS-c and you will find it sold as a pre-workout — a vial you inject to unlock an exercise you have not done yet. That framing has the arrow pointing the wrong way. In the human data, MOTS-c is something the working muscle writes, not something it waits to receive. When researchers biopsied skeletal muscle before and after a hard bout of exercise, endogenous MOTS-c rose nearly twelve-fold and stayed elevated hours into recovery (Reynolds et al., 2021, Nat Commun). Circulating levels climbed during the session and drifted back to baseline within about four hours.

That single fact reorganizes the entire “optimal timing” question. MOTS-c is not the pre-workout; it is closer to the receipt the cell prints once the work is done. The stimulus is the order. If you want more of the peptide, the lever the biology actually responds to is the training and the metabolic state around it — not the clock time of a syringe.

MOTS-c is a 16-amino-acid peptide with an unusual return address: it is encoded not in the nuclear genome but inside a short open reading frame of the mitochondrial 12S rRNA gene — a message written by the cell’s own power plants (Lee et al., 2015, Cell Metab). It belongs to a young class, the mitochondrial-derived peptides, whose founding member was humanin.

Its mechanism is the reason exercise and MOTS-c rhyme. MOTS-c acts on the folate–methionine one-carbon cycle, which backs up the intermediate AICAR — a direct activator of AMPK, the cell’s low-energy sensor. AMPK is the same master switch a hard workout throws: when fuel runs short, AMPK flips the cell from storing to burning, and pushes mitochondrial biogenesis. Under metabolic stress, MOTS-c does something stranger still — it translocates into the nucleus, in an AMPK-dependent way, and binds stress-response transcription factors like NRF2 to switch on antioxidant and metabolic genes (Kim et al., 2018, Cell Metab). A peptide from the mitochondrial genome, reaching into the nuclear one, to help the cell adapt to exactly the kind of energy crunch that training imposes.

So the “exercise-mimetic” label is earned honestly: MOTS-c sits on the AMPK adaptation pathway that exercise recruits. But note the dependency in that diagram — the peptide is a relay in a signal the energy stress starts. That is what makes it induced by training rather than a substitute for it.

If MOTS-c is downstream of AMPK and energy stress, then the interventions that reliably raise it are the ones that create energy stress — and those are lifestyle, not pharmacology. This is the part the vendor framing skips, and it is the part with the strongest evidence behind it.

• Train in a way that actually stresses fuel. The MOTS-c spike in the human data followed a genuine exercise bout, not a stroll. Endurance work and high-intensity intervals both drain cellular energy charge and drive AMPK — the upstream trigger. Intensity and duration that meaningfully deplete the cell are the stimulus; token movement is not.
• Let the recovery window do its job. MOTS-c stayed elevated in muscle hours after the session and only then returned to baseline. The adaptation is written during and just after training, which is a reminder that the recovery period is part of the dose, not dead time — sleep and rest are when the gene program the peptide helped switch on gets executed.
• Respect the energy-availability context. MOTS-c improved insulin sensitivity and blunted diet-induced obesity in mice precisely in the setting of metabolic stress. A body chronically over-fed and under-moved gives AMPK little reason to fire. Periods of genuine energy demand — training, and not eating around the clock — are the physiological context this peptide evolved to answer.
• Don't out-supplement the signal. Because MOTS-c works through AMPK, it lives in the same lane as metformin and AICAR. The lesson from that lane is that the signal is context-dependent: it does the most where there is real metabolic stress to correct, and comparatively little on top of an already well-trained, energy-flexible physiology.

Suppose you set the endogenous story aside and ask the vendor’s question directly: if someone injects MOTS-c, when around training would it make mechanistic sense? The honest answer starts with a caveat that swallows most of it — there is no published human dose-response for native MOTS-c, the performance evidence is preclinical, and the circulating peptide is cleared quickly. Any timing scheme is therefore reasoning from mechanism, not from human trials, and this reference does not give dosing guidance.

On mechanism alone, two logics pull in opposite directions, which is itself the point. One says pair exogenous MOTS-c with the training window, to stack an AMPK activator on top of the AMPK stress the workout already creates. The other says that stacking a mimetic on the real thing may blunt the adaptation you train for — the same worry raised about taking antioxidants around exercise, where damping the stress signal damps the response to it. The field has not resolved which logic wins in humans, and that unresolved tension is the current honest state of the art.

MOTS-c is often lumped with two other peptides that share the mitochondrial address — the mitochondria-targeting drug SS-31 (elamipretide) and the mitochondrial-encoded humanin. The lumping obscures more than it reveals: they answer completely different questions, and only one of them is about the training-timing story at all.

SS-31 is the clearest contrast. It is not a signal and it does not touch AMPK. It is a small synthetic molecule that physically concentrates in the inner mitochondrial membrane and binds cardiolipin — the signature lipid that shapes the cristae where the electron-transport chain lives — helping preserve that architecture and cutting reactive-oxygen leakage. It is structural maintenance, not a message. And its evidence lives in a different world: real clinical trials in mitochondrial disease, including the MMPOWER-3 primary-mitochondrial-myopathy trial, and a first regulatory approval — as elamipretide, for Barth syndrome. If MOTS-c is the receipt the working muscle prints, SS-31 is closer to a repair crew for power plants that are failing for reasons that have nothing to do with your last workout.

Humanin is different again — the family’s cytoprotectant, studied for keeping stressed cells alive rather than for tuning metabolism or performance. Three peptides, one organelle, three unrelated jobs. Only MOTS-c is meaningfully part of a conversation about training.

The interesting future for MOTS-c is not a better injection schedule; it is finishing the human science the mouse work opened. A phase-2 trial of subcutaneous MOTS-c in prediabetes and obesity is the kind of readout that would turn a compelling exercise-induction story into an actual clinical one. Until it reports, the strongest evidence-backed claim remains the humble one: the training does the work, and the peptide is the body’s own record that it happened.

That is the whole premise of this site in miniature. A genuinely elegant mechanism — a peptide the mitochondrial genome writes to help the cell survive an energy crisis — is more interesting, and more honest, than the shortcut it gets marketed as. Understand the arrow, and the timing question answers itself: build the stimulus, and let the cell keep its own receipts.